Diaceutics PLC Trading update (7125E)
08 July 2019 - 4:00PM
UK Regulatory
TIDMDXRX
RNS Number : 7125E
Diaceutics PLC
08 July 2019
8 July 2019
Diaceutics PLC
("Diaceutics" or the "Company")
Trading update
Diaceutics PLC (AIM: DXRX), a provider of data analytics and
implementation services to the global pharmaceutical industry,
announces a trading update for the six months ended 30 June 2019.
Trading has continued in line with market expectations and the
Company remains well positioned in key markets, underpinned by a
strong sales performance.
An increased international footprint has enhanced Diaceutics'
global offering and allowed the Company to acquire new
international clients. The Nexus project is progressing as
planned.
All outstanding debt has now been retired from the balance sheet
resulting in net cash of GBP14.0m.
The Group's interim results are expected to be announced in
early September.
Enquiries:
Diaceutics PLC www.diaceutics.com
Peter Keeling, Chief Executive via Walbrook PR
Officer
Philip White, Chief Financial
Officer
Cenkos Securities plc (Nominated adviser
and broker) +44 (0) 20 3861 6630
Callum Davidson / Giles
Balleny
Michael Johnson (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Diaceutics
Diaceutics PLC is a leading diagnostics data analytics and
implementation services provider for global pharmaceutical
companies. The Company, quoted on the Alternative Investment Market
(AIM) of the London Stock Exchange, is enabling pharma to
accelerate their market penetration and achieve a better return on
precision medicine therapies by helping them to revolutionise
patient testing. By generating insights from its data lake of
clinical laboratory testing data and other data, Diaceutics helps
pharma understand and leverage the diagnostic landscape through
initiatives that improve patient testing, leading to better
treatment outcomes. The Company works with more than 30 global
pharmaceutical companies across hundreds of precision medicine
projects. The Company employs a leading global group of experts
from the laboratory, diagnostic and pharmaceutical industries.
www.diaceutics.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
TSTUGUQAMUPBURQ
(END) Dow Jones Newswires
July 08, 2019 02:00 ET (06:00 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024